Colorectal Cancer is the second-leading cause of cancer death for men and women in the US.
A colorectal cancer diagnosis is scary.
Our Path to a Cure report is our plan for the future. This plan is not just for Fight CRC, but for everyone who is willing to champion this cause.
Making an impact since 2005.
Raise Awareness. Be an Advocate. Host an Event.
Clinical trial’s patient recruitment status
Phase of the clinical trial that is recruiting (I, II, or III)
A flag to indicate whether the trial is an immunotherapy trial
Prior Immunotherapy Allowed
Whether the clinical trial is open to patients who have received prior immunotherapy
A flag to indicate whether the trial is specifically targeting colon cancer, rectal cancer, or colorectal cancer patients
Therapeutics used in the clinical trial
Phase III BREAKWATER trial. Only for patients with BRAF V600E–mutated, stage IV (metastatic) CRC, who are about to the receive their FIRST LINE of treatment, in the metastatic setting. Trial compares:
1. encorafenib (Braftovi) plus cetuximab (Erbitux) vs.
2. encorafenib (Braftovi) plus cetuximab (Erbitux) plus standard-of-care (SOC) chemotherapy vs.
3. chemotherapy alone